Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

Conference call to provide business updates today, August 6 at 1:30 p.m. PT / 4:30 p.m. ET FOSTER CITY, Calif., August 06, ...

Courtney Kidd, 37, is in need of a new liver after being diagnosed with a rare condition called Primary Sclerosing ...

Medical and scientific innovation are in a fast lane closely pursued by digital advances but their dynamism can mute a vital ...

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Astria took the candidate, a monoclonal antibody inhibitor of plasma kallikrein called navenibart, into a late-stage study off the back of a phase 1b/2 trial last year that tied the drug to up to a 92 ...

The biopharmaceutical company posted a second quarter loss of $0.12 per share, beating analyst estimates of a $0.33 loss by $0.21. Revenue reached $127.8 million, substantially outpacing the consensus ...

Tharimmune, Inc. (NASDAQ:THAR), ("Tharimmune" or the "Company), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and ...

Harvard-trained hepatologist Dr. Saurabh Sethi advises that skin changes can be early indicators of liver issues. Jaundice, ...

Company closes approximately $5.47 million in equity financing in 2Q/3Q25-TH104 potentially fills a critical National Security Need against Weaponized Fentanyl–TH023 may fulfill the promise of ...

Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure.

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.